Announcements - OBI Pharma 台灣浩鼎

2020.Nov.23

OBI received the reply from FDA about the Investigational Device Exemption (IDE) of Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424

2020.Nov.06

Announcement of 2020 Q3 financial reports submitted to the board of directors

2020.Oct.15

OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (the agreement of share exchange and cooperation signed, and trading counterparts designated)

2020.Oct.06

OBI filed an application of Investigational Device Exemption (IDE) for Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424, to FDA

2020.Sep.28

OBI capital increases by issuance of stocks as the consideration of share exchange cooperation with Amaran Biotechnology Inc.

2020.Sep.28

Announcement of press release of press conference on Sept 28, 2020

2020.Sep.28

Board of directors resolved to license DNA sequence of OBI-888 to AP Bioscience Inc. for bispecific antibody development

2020.Sep.28

Board of directors’ resolution on licensing of OBI-833, OBI-888 and OBI-999 in China (including Hong Kong and Macao)

2020.Sep.28

New Appointment of Compensation Committee Member

2020.Aug.25

TFDA clearance for Phase 1 clinical study for active immunotherapeutic cancer vaccine, OBI-866

News

Latest News

Events

Latest events